CymaBay Therapeutics Inc (NASDAQ:CBAY) was the recipient of some unusual options trading activity on Monday. Traders acquired 1,126 call options on the stock. This is an increase of 993% compared to the average daily volume of 103 call options.
A number of brokerages have recently issued reports on CBAY. Cantor Fitzgerald reiterated a “buy” rating and set a $16.00 price objective on shares of CymaBay Therapeutics in a report on Friday, March 16th. HC Wainwright reiterated a “buy” rating and set a $18.00 price objective (up from $12.00) on shares of CymaBay Therapeutics in a report on Wednesday, January 24th. Oppenheimer set a $15.00 price objective on shares of CymaBay Therapeutics and gave the company a “buy” rating in a report on Wednesday, January 10th. Piper Jaffray Companies reiterated a “buy” rating and set a $16.00 price objective on shares of CymaBay Therapeutics in a report on Friday, March 16th. Finally, Leerink Swann reiterated a “buy” rating and set a $16.00 price objective on shares of CymaBay Therapeutics in a report on Tuesday, November 28th. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $17.78.
In other CymaBay Therapeutics news, Director Kurt Von Emster sold 4,300 shares of CymaBay Therapeutics stock in a transaction on Friday, January 5th. The shares were sold at an average price of $10.21, for a total value of $43,903.00. Following the completion of the sale, the director now directly owns 90,000 shares of the company’s stock, valued at $918,900. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Over the last ninety days, insiders sold 978,140 shares of company stock valued at $11,761,941. Insiders own 15.10% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC boosted its holdings in CymaBay Therapeutics by 56.2% during the fourth quarter. Virtu Financial LLC now owns 24,735 shares of the biopharmaceutical company’s stock worth $228,000 after purchasing an additional 8,899 shares during the last quarter. Sigma Planning Corp boosted its holdings in CymaBay Therapeutics by 82.0% during the fourth quarter. Sigma Planning Corp now owns 27,300 shares of the biopharmaceutical company’s stock worth $251,000 after purchasing an additional 12,300 shares during the last quarter. Schwab Charles Investment Management Inc. purchased a new position in CymaBay Therapeutics during the fourth quarter worth about $115,000. Raymond James & Associates boosted its holdings in CymaBay Therapeutics by 50.6% during the fourth quarter. Raymond James & Associates now owns 53,148 shares of the biopharmaceutical company’s stock worth $489,000 after purchasing an additional 17,848 shares during the last quarter. Finally, Goldman Sachs Group Inc. purchased a new position in CymaBay Therapeutics during the fourth quarter worth about $197,000. Institutional investors and hedge funds own 61.36% of the company’s stock.
CBAY stock opened at $13.20 on Wednesday. CymaBay Therapeutics has a twelve month low of $3.16 and a twelve month high of $15.59. The firm has a market cap of $803.82, a PE ratio of -15.90 and a beta of 1.96. The company has a current ratio of 6.35, a quick ratio of 6.35 and a debt-to-equity ratio of 0.04.
CymaBay Therapeutics (NASDAQ:CBAY) last released its quarterly earnings results on Thursday, March 15th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.06. The firm had revenue of $5.20 million for the quarter, compared to analysts’ expectations of $1.25 million. analysts predict that CymaBay Therapeutics will post -0.86 EPS for the current year.
WARNING: “CymaBay Therapeutics Target of Unusually High Options Trading (CBAY)” was first posted by Stock Observer and is owned by of Stock Observer. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://www.thestockobserver.com/2018/03/21/cymabay-therapeutics-target-of-unusually-high-options-trading-cbay.html.
CymaBay Therapeutics Company Profile
CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.
Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.